Crystalline bromodomain inhibitors

1. An isolated crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide, wherein the crystalline form has a powder X-ray diffraction pattern comprising three or more 2θ peak values ±0.2 selected from the group consisting of: 6.2°, 9.0°, 12.3°, 12.6°, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

2. An isolated crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide, wherein the crystalline form has a powder X-ray diffraction pattern comprising the following 2θ peak values ±0.2: 6.2°, 9.0°, 11.0°, 12.3°, 12.6°, 13.1°, 14.1°, 15.6°, 16.4°, 16.5°, 16.9°, 17.8°, 18.1°, 18.3°, 18.9°, 20.4°, 21.1°, 21.6°, 21.8°, 22.1°, 22.9°, 23.2°, 24.4°, 24.7°, 25.6°, 26.3°, 27.0°, and 27.3°.

3. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising three, four, five, or six 2θ peak values ±0.2 selected from the group consisting of 6.2°, 9.0°, 12.3°, 12.6, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

4. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising six 2θ peak values ±0.2 selected from the group consisting of 6.2°, 9.0°, 12.3°, 12.6, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

5. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising five 2θ peak values ±0.2 selected from the group consisting of 6.2°, 9.0°, 12.3°, 12.6, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

6. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising four 2θ peak values ±0.2 selected from the group consisting of 6.2°, 9.0°, 12.3°, 12.6, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

7. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising three 2θ peak values ±0.2 selected from the group consisting of 6.2°, 9.0°, 12.3°, 12.6, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

8. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising the following 2θ peak values ±0.2: 6.2°, 9.0°, 12.3°, 12.6°, and 15.6°.

9. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising the following 2θ peak values ±0.2: 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

10. The crystalline form of claim 2 having a powder X-ray diffraction pattern comprising peak values ±0.2 at 2θ positions 6.2°, 9.0°, 12.3°, 12.6°, 13.1°, 14.1°, 16.4°, 16.5°, 16.9°, 17.8°, 18.1°, 18.3°, and 18.9°.

11. The crystalline form of claim 2 having a powder X-ray diffraction pattern comprising peak values ±0.2 at 2θ positions 6.2°, 9.0°, 12.3°, 12.6°, 13.1°, 14.1°, 18.1°, and 18.9°.

12. The crystalline form of claim 2 having a powder X-ray diffraction pattern comprising peak values ±0.2 at 2θ positions 6.2°, 9.0°, 12.3°, 12.6°, 13.1°, and 18.1°.

13. The crystalline form of claim 2 having a powder X-ray diffraction pattern comprising peak values ±0.2 at 2θ positions 9.0°, 12.3°, 12.6°, 13.1°, and 18.1°.

14. The crystalline form of claim 1 having a differential scanning calorimetry thermogram endotherm between 240 and 242° C.

15. The crystalline form of claim 1 having a differential scanning calorimetry thermogram endotherm at approximately 241° C.

16. A pharmaceutical composition comprising an isolated crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 , and at least one pharmaceutically acceptable carrier.

17. A method for treating cancer in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof.

18. The method of claim 17 wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.

19. A method of making a pharmaceutical composition comprising N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and a pharmaceutically acceptable carrier, comprising:

mixing an isolated crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide, wherein the crystalline form has a powder X-ray diffraction pattern comprising three or more 2θ peak values ±0.2 selected from the group consisting of: 6.2°, 9.0°, 12.3°, 12.6°, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°, with a pharmaceutically acceptable carrier.

20. A composition comprising greater than 90% (w/w) crystalline form II of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide, wherein the crystalline form has a powder X-ray diffraction pattern comprising three or more 2θ peak values ±0.2 selected from the group consisting of: 6.2°, 9.0°, 12.3°, 12.6°, 15.6°, 22.1°, 25.6°, 26.3°, 27.0°, and 27.3°.

21. A method for treating an acute kidney disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease.

22. A method for treating a chronic kidney disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof, wherein said chronic kidney disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

23. A method for treating a disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, cardiac myopathy, cardiac hypertrophy, chronic obstructive pulmonary disease (COPD), Crohn's disease, dermatitis, eczema, giant cell arteritis, glomerulonephritis, heart failure, hepatitis, hypophysitis, inflammatory bowel disease, Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis, myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis, systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis.

24. A method for treating an acquired immunodeficiency syndrome (AIDS) in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof.

25. A method for treating a disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of: obesity, dyslipidemia, hypercholesterolemia, Alzheimer's disease, metabolic syndrome, hepatic steatosis, type II diabetes, insulin resistance, diabetic retinopathy and diabetic neuropathy.

26. A method of contraception in a male subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide according to claim 1 and at least one pharmaceutically acceptable carrier, to a subject in need thereof.